Loading...
•
Sep 30, 2022
Arvinas Q3 2022 Earnings Report
Reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
Key Takeaways
Arvinas reported revenues of $30.3 million and a net loss of $66.2 million for the third quarter of 2022. The company is on track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer.
Initiated activity to enroll four new clinical trials with ARV-471.
Began a Phase 2 trial with ARV-766.
Strengthened executive team and Board of Directors.
Expect the initiation of two Phase 3 trials with ARV-471 in patients with metastatic breast cancer by the end of this year, and a Phase 3 trial with bavdegalutamide in men with metastatic castrate resistant prostate cancer in the second half of 2023.
Revenue by Segment
Forward Guidance
Arvinas believes its cash, cash equivalents, restricted cash and marketable securities as of September 30, 2022 is sufficient to fund planned operating expenses and capital expenditure requirements multiple years beyond 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...